Air Street Capital

Developer of drug discovery platform designed for radically accelerating small molecule drug discovery and finding pharmaceutical compounds for medically important targets. The company's technology rapidly analyzes compounds by combining machine learning with DNA-encoded libraries to generate enormous amounts of useful data and parallel biochemical experiments using proprietary artificial intelligence (AI) models, enabling researchers to develop new drugs.

Developer of business metrics and insights software designed to find a better way to work. The company's software quantifies bottlenecks to measure growth, provides more visibility of work, identifies key success indicators and productivity issues, optimizes software delivery, and improves business communications, enabling clients to build a culture of continuous improvement and generate profit.

Gandeeva Therapeutics is a biotechnology company focused on drug discovery, utilizing a proprietary platform that integrates cryogenic electron microscopy and machine learning. This platform enables the detailed characterization of protein-drug interactions at the atomic level, facilitating insights into protein function and interactions. The company's approach includes target prediction and validation, hit identification through virtual and fragment library screening, and lead optimization. Gandeeva Therapeutics is developing innovative therapeutics aimed at key protein-protein interactions, particularly in oncology, with a robust preclinical pipeline that addresses challenging cancers using novel protein interaction modulators, such as interfacial glues and allosteric inhibitors. This methodology aims to reduce the risks associated with late-stage clinical failures in drug development.

Developer of drug discovery platform designed for radically accelerating small molecule drug discovery and finding pharmaceutical compounds for medically important targets. The company's technology rapidly analyzes compounds by combining machine learning with DNA-encoded libraries to generate enormous amounts of useful data and parallel biochemical experiments using proprietary artificial intelligence (AI) models, enabling researchers to develop new drugs.

InVivo AI is a Montreal-based company founded in 2017 that specializes in using artificial intelligence to enhance pharmaceutical research and development. The company primarily focuses on preclinical toxicology, aiming to improve the efficiency and effectiveness of drug development processes. By leveraging advanced AI technologies, InVivo AI seeks to transform traditional methodologies in the pharmaceutical industry, ultimately contributing to faster and more reliable outcomes in drug safety assessments.

Intenseye Inc. is a San Jose, California-based company that develops an artificial intelligence-powered video analytics platform designed to enhance safety and operational efficiency in various environments. Founded in 2018, the platform enables users to connect existing cameras quickly, without the need for additional hardware or sensors. It leverages in-house deep learning models to analyze images and videos, focusing on aspects such as worker body posture, the use of personal protective equipment, and violations of safety protocols. This real-time analysis assists organizations in mitigating workplace accidents and improving overall safety, making it a valuable tool for industries like occupational health and safety, retail consumer analytics, and outdoor advertising.

Modern Intelligence is a technology company based in San Jose, California, founded in 2020. It specializes in developing advanced artificial intelligence solutions for the defense sector, utilizing proprietary methodologies derived from information and complexity theory. The company's innovative hierarchical approach enhances the capabilities of AI, allowing for significant scaling advantages over traditional neural networks. This technology enables high accuracy in few-shot learning, allowing military applications to tackle novel problems and address previously unsolvable challenges. Additionally, Modern Intelligence has created a maritime sensor platform that facilitates the integration of AI into military operations. This platform enhances the ability of command and control systems to track, analyze, and learn about maritime targets during missions, thereby improving targeting analysis and decision-making processes with minimal data samples.

Gourmey is a pioneering company based in Paris, France, that specializes in the development and production of ethical foie gras derived from duck cells. Founded in 2019, it is recognized as France's first cultivated meat company, aiming to revolutionize the meat industry by offering a humane and sustainable alternative to traditional practices. Gourmey's innovative process involves cultivating duck cells in a controlled laboratory environment, where they are provided with optimal conditions, including temperature, nutrients, and space to grow. This method allows the company to produce foie gras without the need for force-feeding or slaughter, aligning with its commitment to health, environmental sustainability, and animal welfare.

Intenseye Inc. is a San Jose, California-based company that develops an artificial intelligence-powered video analytics platform designed to enhance safety and operational efficiency in various environments. Founded in 2018, the platform enables users to connect existing cameras quickly, without the need for additional hardware or sensors. It leverages in-house deep learning models to analyze images and videos, focusing on aspects such as worker body posture, the use of personal protective equipment, and violations of safety protocols. This real-time analysis assists organizations in mitigating workplace accidents and improving overall safety, making it a valuable tool for industries like occupational health and safety, retail consumer analytics, and outdoor advertising.

V7 Ltd is a London-based company that specializes in developing a toolkit for computer vision artificial intelligence. Founded in 2018, V7 emerged from stealth mode to introduce V7 Darwin, an innovative image labeling platform that enables the creation of training data for computer vision projects with minimal human intervention. The company provides high-quality annotated datasets, including images, videos, and medical imaging files, which are essential for training AI models. V7's solutions cater to various industries, including healthcare, life sciences, manufacturing, autonomous driving, and agri-tech, serving notable clients such as Merck, GE Healthcare, and Toyota. In addition to V7 Darwin, the company offers V7 Neurons, a suite of pre-trained image recognition applications designed for specific industry needs, including defect recognition, livestock monitoring, and video anonymization. V7 aims to enhance the efficiency and accuracy of AI development by streamlining the annotation process and enabling continuous learning from training data.

Allcyte is a biotech start-up company focused on functional drug testing in primary human material. With our Pharmacoscopy high-content imaging platform and AI-supported image analysis pipelines, our mission is to bring the next generation of personalized medicine to cancer patients and treating physicians, and support pharmaceutical companies to focus their drug development efforts on the right molecules in the right indications. We enable research through the image-based quantification of single-cell phenotypes - all performed directly in primary patient material with minimal amounts of manipulation and requiring minimal amounts of sample. We integrate these data using cutting edge methods of statistics and machine learning to generate actionable insights for our customers. Our mission is to help you make the best possible biomedical decisions.

LabGenius Ltd is a biopharmaceutical company based in London, focused on the discovery and development of protein therapeutics to address unmet medical needs, such as Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven platform that integrates advanced technologies from synthetic biology, robotics, and automation. At the core of its operations is EVA, a robotic scientist capable of designing, conducting, and learning from its own experiments, which enhances the protein engineering process. This innovative approach allows LabGenius to create protein drugs with optimized properties, such as improved protease stability and tissue penetration, ultimately providing physicians with access to next-generation therapeutics developed through cutting-edge methodologies.

Mission Barns, Inc., founded in 2018 and based in Berkeley, California, specializes in producing cell-cultured meat from animal cells. The company cultivates animal cells in a nutrient-rich environment, allowing for the sustainable growth of meat while minimizing the negative impacts associated with traditional animal farming. By leveraging advancements in biotechnology and food science, Mission Barns aims to provide juicy and savory meat products in a more efficient and environmentally friendly manner. The company's approach is designed to contribute to a more sensible food system, addressing the growing demand for sustainable food solutions.

Vtrus specializes in the development of advanced robotics technology, focusing on the ABI (Autonomy Brain Implant), which is a modular unit designed to enhance robots' understanding of their environment. This system simplifies the complexities of perception, planning, and control by offering a straightforward message-passing interface, facilitating quicker implementation of robotics projects. In addition to the ABI, Vtrus also creates autonomous inspection drones that autonomously gather critical data for monitoring industrial facilities. These drones are equipped with an array of sensors, including cameras, thermal imagers, and three-dimensional scanners, enabling them to produce complementary 3D map scans along with geo-anchored multimedia content. This technology allows for more efficient post-inspection analysis, significantly improving data collection capabilities while minimizing the risks associated with accessing hazardous or hard-to-reach locations.

Mission Barns, Inc., founded in 2018 and based in Berkeley, California, specializes in producing cell-cultured meat from animal cells. The company cultivates animal cells in a nutrient-rich environment, allowing for the sustainable growth of meat while minimizing the negative impacts associated with traditional animal farming. By leveraging advancements in biotechnology and food science, Mission Barns aims to provide juicy and savory meat products in a more efficient and environmentally friendly manner. The company's approach is designed to contribute to a more sensible food system, addressing the growing demand for sustainable food solutions.